{
    "clinical_study": {
        "@rank": "8256", 
        "arm_group": [
            {
                "arm_group_label": "double blinded Fingolimod 6 mos + open label fingolimod 6 mos", 
                "arm_group_type": "Experimental", 
                "description": "Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily"
            }, 
            {
                "arm_group_label": "Placebo 6 mos + open label fingolimod 6 mos", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China"
        }, 
        "brief_title": "Safety and Efficacy of Fingolimod in MS Patients in China", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Multiple Sclerosis (Relapsing Remitting)", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -Patients must have relapsing remitting multiple sclerosis\n\n        Exclusion Criteria:\n\n        Patients with:\n\n          -  History of chronic immune disease\n\n          -  Certain cancers\n\n          -  Uncontrolled diabetes\n\n          -  Certain eye disorders -Negative for varicella\n\n          -  zoster virus IgG antibodies\n\n          -  Certain hepatic conditions\n\n          -  Low white blood cell count\n\n          -  On certain immunosuppressive medications or heart medications\n\n          -  Certain heart conditions or certain lung conditions\n\n          -  Inability to undergo MRI scans -Diagnosis of Neuromyelitis optica.\n\n          -  Other protocol defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01941004", 
            "org_study_id": "CFTY720D2315"
        }, 
        "intervention": [
            {
                "arm_group_label": "double blinded Fingolimod 6 mos + open label fingolimod 6 mos", 
                "description": "Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily", 
                "intervention_name": "fingolimod", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo 6 mos + open label fingolimod 6 mos", 
                "description": "Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily", 
                "intervention_name": "Placebo (6mos) + open label fingolimod (6 mos)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fingolimod"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "multiple sclerosis (MS)", 
            "relapsing remitting multiple sclerosis (RRMS)", 
            "fingolimod"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis", 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Cumulative number of new/newly enlarged T2 lesions over 6 months", 
            "measure": "number of new/newly enlarged T2 MRI lesions over 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01941004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The annualized relapse rate (ARR) is identified as the average number of confirmed relapses per year (the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses will include all the confirmed relapses during the study. The time spent in the study will correspond to the observation period for all the relapses from first dose on the study drug to end of study.", 
                "measure": "annualized relapse rate (ARR)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "number of Gd-enhancing T1 lesions", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Based on frequency of adverse events (the number and percentage of patients having any AE by primary system organ class and preferred term) and on the incidence of clinically notable abnormalities", 
                "measure": "Safety and tolerability of fingolimod 0.5 mg compared to placebo", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}